Background: Recent studies have revealed the pivotal role of Th17 cells and interleukin-17 (IL-17) in plaque psoriasis development and treatment outcome. The IL-17 family consists of 6 structurally related cytokines (IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, IL-17F), of which IL-17A and IL-17F mediate similar biological effects. Objectives: The aim of this study was to evaluate an association between the IL17A (-197G>A; rs2275913) and IL17F (rs763780: T>C; rs11465553: G>A; rs2397084: T>C) polymorphisms with psoriasis susceptibility as well as response to topical and combined topical with narrow-band ultraviolet B (NB-UVB) therapy in a Polish population. Methods: Association study involving 407 psoriasis patients and 205 healthy controls. Treatment efficacy was analyzed in 207 patients with mild psoriasis (Psoriasis Area and Severity Index; PASI 3-12) and moderate psoriasis (PASI 12-18), who were randomly subjected to topical or combined topical and NB-UVB treatment. The polymorphisms were evaluated by RT-PCR. Results: No statistically significant differences between psoriasis patients and controls were found in the frequency of the evaluated IL17A and IL17F genotypes and haplotypes. The IL17A or IL17F polymorphisms were not associated with treatment outcome measures: efficacy of treatment at the eighth week of the study and PASI change after topical or combined topical and NB-UVB therapy. However, IL17F rs2397084 variant allele C carriers required a significantly higher number of NB-UVB irradiations in comparison to TT homozygotes (15.5 ± 11.4 vs. 11.1 ± 11.9, p = 0.047) to produce a positive clinical response. Conclusion: It can be stated that the IL17A and IL17F polymorphisms are not markers of susceptibility to psoriasis. However, the IL17F polymorphism may affect the response to NB-UVB therapy.
Interleukin-6 (IL-6) is implicated in the pathogenesis of psoriasis as well as in its treatment efficacy. The aim of this study of 406 patients with psoriasis and 203 healthy controls was to evaluate the association between the IL6 À174G>C (rs1800795) polymorphism and psoriasis susceptibility, as well as treatment efficacy. The frequency of genotype GG (33.7% vs 20.7%; P = 0.00022; OR = 0.51, 95% confidence interval 0.34-0.76) and of allele G (56.2% vs 46.8%; P = 0.0023) was significantly higher in the psoriasis group compared with controls. No polymorphism variants were associated with better response to topical or combined topical/narrow-band ultraviolet B (NB-UVB) treatment. We conclude that the IL6 À174G>C polymorphism can be a marker of susceptibility to psoriasis, with an almost twofold increased risk of the disease in individuals carrying the GG genotype; however, it was not associated with treatment response to topical and/or NB-UVB therapy.
Interleukin-6 (IL-6) is implicated in the pathogenesis of psoriasis as well as in its treatment efficacy. The aim of this study of 406 psoriasis patients and 203 healthy controls was to evaluate the association between the IL6 À174G>C (rs1800795) polymorphism and psoriasis susceptibility, as well as treatment efficacy. The frequency of genotype GG (33.7% vs. 20.7%; p = 0.00022; OR = 0.51, 95% confidence interval 0.34-0.76) and of allele G (56.2% vs. 46.8%; p = 0.0023) was significantly higher in the psoriasis group compared to controls. No polymorphism variants were associated with better response to topical or combined topical/ narrow-band ultraviolet B (NB-UVB) treatment. We conclude that the IL6 À174G>C polymorphism can be a marker of susceptibility to psoriasis, with an almost 2-fold increased risk of the disease in individuals carrying the GG genotype; however, it was not associated with treatment response to topical and/or NB-UVB therapy.http://dx.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.